An overview of matrix metalloproteinases in the pathogenesis and treatment of abdominal aortic aneurysms.
Recent basic and clinical research has established a link between the pathogenesis of abdominal aortic aneurysms (AAA) and matrix metalloproteinases (MMP). The discovery of the influence of MMPs on in vitro and in vivo aneurysm development has yielded promising information that may eventually decode the pathogenetic factors affecting the initiation and growth rate of AAAs. In this review, an analysis of MMPs involved in AAA disease is presented, including the data from recent research studies and planned clinical drug trails designed to retard the AAA growth by inhibiting MMP activity.
Keeling
W Brent
WB
Division of Vascular and Endovascular Surgery, University of South Florida College of Medicine, Tampa, FL 33606, USA.
Armstrong
Paul A
PA
Stone
Patrick A
PA
Bandyk
Dennis F
DF
Shames
Murray L
ML
D000818:Animals; D017544:Aortic Aneurysm, Abdominal / Q000201:enzymology* / Q000503:physiopathology* / Q000628:therapy; D015415:Biomarkers / Q000378:metabolism; D001707:Biopsy, Needle; D006801:Humans; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D020782:Matrix Metalloproteinases / Q000032:analysis / Q000378:metabolism*; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000378:metabolism; D019717:Tissue Inhibitor of Metalloproteinase-3 / Q000378:metabolism; D019714:Tissue Inhibitor of Metalloproteinases / Q000378:metabolism*; D016896:Treatment Outcome
D015415:Biomarkers; D019715:Tissue Inhibitor of Metalloproteinase-1; D019717:Tissue Inhibitor of Metalloproteinase-3; D019714:Tissue Inhibitor of Metalloproteinases; D019716:Tissue Inhibitor of Metalloproteinase-2; D020782:Matrix Metalloproteinases